ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,460.48
-0.41%
Dow Jones
39,118.86
-0.12%
US Dollar vs MXN
18.3386
0.00%
Brent Oil
84.85
0.00%
Bitcoin
61,537.42
1.06%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Verona Pharma Plc (VRNA)

  7. Verona Pharma Plc (VRNA) Noticias

VRNA

Verona Pharma (VRNA)

Verona Pharma Plc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VRNA
FechaHoraFuenteTítuloSímboloCompañía
26/06/202415:57GlobeNewswire Inc.Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)NASDAQ:VRNAVerona Pharma Plc
10/05/202408:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRNAVerona Pharma Plc
10/05/202407:53Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VRNAVerona Pharma Plc
09/05/202406:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRNAVerona Pharma Plc
09/05/202406:15GlobeNewswire Inc.Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
09/05/202406:00GlobeNewswire Inc.Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSNASDAQ:VRNAVerona Pharma Plc
02/05/202401:00GlobeNewswire Inc.Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024NASDAQ:VRNAVerona Pharma Plc
25/04/202401:00GlobeNewswire Inc.Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
08/03/202415:18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VRNAVerona Pharma Plc
07/03/202420:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRNAVerona Pharma Plc
04/03/202401:00GlobeNewswire Inc.Andrew Fisher Joins Verona Pharma as General CounselNASDAQ:VRNAVerona Pharma Plc
29/02/202408:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VRNAVerona Pharma Plc
29/02/202401:00GlobeNewswire Inc.Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
15/02/202401:00GlobeNewswire Inc.Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
05/02/202417:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRNAVerona Pharma Plc
05/02/202415:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRNAVerona Pharma Plc
01/02/202401:00GlobeNewswire Inc.Michael Austwick Joins Verona Pharma as Non-Executive DirectorNASDAQ:VRNAVerona Pharma Plc
03/01/202401:00GlobeNewswire Inc.Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VRNAVerona Pharma Plc
02/01/202401:00GlobeNewswire Inc.Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules CapitalNASDAQ:VRNAVerona Pharma Plc
17/11/202301:00GlobeNewswire Inc.Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP AwardNASDAQ:VRNAVerona Pharma Plc
08/11/202301:00GlobeNewswire Inc.Verona Pharma Announces November 2023 Investor Conference ParticipationNASDAQ:VRNAVerona Pharma Plc
02/11/202302:04GlobeNewswire Inc.Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
19/10/202301:00GlobeNewswire Inc.Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
06/10/202301:00GlobeNewswire Inc.Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023NASDAQ:VRNAVerona Pharma Plc
03/10/202301:00GlobeNewswire Inc.Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023NASDAQ:VRNAVerona Pharma Plc
11/09/202301:00GlobeNewswire Inc.Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPDNASDAQ:VRNAVerona Pharma Plc
06/09/202301:00GlobeNewswire Inc.Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023NASDAQ:VRNAVerona Pharma Plc
31/08/202301:00GlobeNewswire Inc.Christina Ackermann Joins Verona Pharma as Non-Executive DirectorNASDAQ:VRNAVerona Pharma Plc
03/08/202301:00GlobeNewswire Inc.Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
26/07/202301:00GlobeNewswire Inc.Verona Pharma to Present at 43rd Annual Canaccord Growth ConferenceNASDAQ:VRNAVerona Pharma Plc
 Showing the most relevant articles for your search:NASDAQ:VRNA

Su Consulta Reciente

COIN
FRWCUSD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados